NA
CORT icon

Neuburgh Advisers’s Corcept Therapeutics CORT Stock Holding History

Neuburgh Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,468
Closed -$228K – 923
2019
Q2 		$228K Buy
20,468
+1,326
+7% +$14.8K 0.01% 657
2019
Q1 		$225K Hold
19,142
– – 0.01% 647
2018
Q4 		$256K Buy
19,142
+1,530
+9% +$20.2K 0.01% 578
2018
Q3 		$247K Buy
17,612
+4,828
+38% +$67.5K 0.01% 655
2018
Q2 		$201K Hold
12,784
– – 0.01% 643
2018
Q1 		$210K Buy
+12,784
New +$237K 0.01% 626

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Neuburgh Advisers's CORT Position: Q3 2019 in Review

Neuburgh Advisers sold out of Corcept Therapeutics (CORT) in Q3 2019, closing a stake of 20,468 shares — an estimated $228K sold.

Neuburgh Advisers first reported a position in CORT in Q1 2018 and held it in 6 quarters. The position peaked at $256K in Q4 2018. 193 funds tracked by Wall St. Rank hold CORT as of Q3 2019.

  • Neuburgh Advisers reported no remaining Corcept Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Neuburgh Advisers sold 20,468 Corcept Therapeutics shares in Q3 2019, an estimated $228K.
  • Neuburgh Advisers first reported a position in Corcept Therapeutics in Q1 2018 and held it in 6 quarters.
  • Neuburgh Advisers's Corcept Therapeutics position peaked at $256K in Q4 2018.
  • 193 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.